Purpose, strategy and culture

1:48

View video on Youtube

We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. We’re working to get better at finding them in ways that are faster, more effective, and more predictable. This is reflected in the continued success of our R&D pipeline, which saw significant progress in 2022. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.

R&D approach

New approvals since 2017
20+
Potential new vaccines and medicines in phase III and registration since 2017
23
Vaccines and medicines in our pipeline
68

How we innovate

We’re confident in our future. Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery by 2026. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.

Investors

Patients: packs of medicines and doses of vaccines delivered in 2022
2.3bn
Shareholders: per share dividend in 2022
61.25p
Society: corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes
£1.3bn

Our latest performance figures

Why invest in GSK?

Navthumb Stvg 03 2022 Port 32 Eagle Orange 1 (1)

Being a responsible business means getting ahead of disease together in the right way. We therefore need to consider ESG impacts across everything we do, from the lab to the patient. We have identified six ESG focus areas that address what is most material to our business and the issues that matter to our stakeholders. These focus areas are access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, product governance.

Responsibility

Our ESG performance

Our strategy

GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,

Our R&D approach

Partner with GSK

Our portfolio

Vaccines

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, one and a half million doses of our vaccines are administered daily, and around 40% of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. For GSK this includes our cancer medicines that have life-changing potential for patients. We’re also developing medicines for immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve health and make life better for millions of people all over the world. For more than 50 years, we’ve helped millions of people with respiratory conditions to breathe more easily, including the first inhalers in 1969, and we remain the industry leader in respiratory science.

How we prevent and treat disease

Our therapeutic areas

Infectious diseases

Two thirds of the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

HIV

Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.

Respiratory/ immunology

We’re focused on unlocking the science of the immune system to understand how the body reacts.

Oncology

Our expertise in oncology allows us to bring groundbreaking cancer therapies to our patients.

Opportunity-driven

As well as our portfolio across therapy areas, we pursue other opportunities where the emerging science indicates the potential for important new opportunities to have major impact in addressing unmet need. This includes the work we are doing to help the one in seven of 700 million chronic kidney disease sufferers with anaemia.